Table 3.
Laboratory Examinations and Imaging Characteristics at Admission in Patients With COVID-19 or H1N1
| Variable | Total (N = 148) | COVID-19 (n = 73) | H1N1 (n = 75) | P Value |
|---|---|---|---|---|
| Blood routine test | ||||
| WBC (×109/L) | 6.9 (4.6, 10.0) | 7.2 (4.8, 10.0) | 6.6 (4.3, 10.1) | .511 |
| Neutrophil granulocyte (×109/L) | 6.0 (3.3, 9.1) | 6.3 (3.2, 9.2) | 5.5 (3.4, 9.0) | .511 |
| Neutrophil granulocyte, % | 86.0 (77.9, 91.2) | 85.4 (75.4, 90.2) | 86.6 (80.0, 92.0) | .439 |
| Lymphocyte (×109/L) | 0.6 (0.4, 0.8) | 0.7 (0.5, 0.9) | 0.5 (0.4, 0.8) | .251 |
| Lymphocyte, % | 9.2 (5.0, 13.8) | 9.2 (6.1, 16.0) | 9.2 (4.8, 12.3) | .930 |
| Hemoglobin, g/L | 126.0 (105.5, 138.5) | 136.0 (127.5, 147.0) | 124 (104.5, 138.0) | .094 |
| Platelet (×109/L) | 129.0 (99, 176.5) | 166.5 (145.5, 192.5) | 123.0 (96.5, 173.0) | .117 |
| Coagulation function | ||||
| Prothrombin time, s | 13.0 (12.0, 14.8) | 14.2 (12.6, 15.6) | 12.1 (11.5, 13.8) | < .001 |
| Activated partial thromboplastin time, s | 33.8 (28.8, 39.9) | 36.2 (30.4, 40.8) | 31.6 (26.2, 37.8) | .020 |
| D-dimer, mg/L | 2.4 (0.6, 6.6) | 0.6 (0.4, 3.4) | 4.2 (1.8, 9.2) | < .001 |
| Biochemical test | ||||
| Albumin, g/L | 30.7 (26.8, 33.4) | 33.2 (30.8, 36.2) | 27.3 (24.8, 30.8) | < .001 |
| AST, U/L | 29.5 (21.0, 51.0) | 25.5 (20.0, 42.5) | 70.0 (49.0, 123.0) | < .001 |
| ALT, U/L | 52.0 (31.0, 88.0) | 34.5 (24.0, 61.0) | 35.0 (23.0, 55.0) | .742 |
| Total bilirubin, μmol/L | 11.1 (8.2, 16.8) | 9.8 (8.0, 14.5) | 12.1 (9.1, 18.5) | .208 |
| Direct bilirubin, μmol /L | 4.6 (2.7, 7.2) | 3.1 (2.2, 5.4) | 6.2 (3.4, 10.3) | < .001 |
| Urea nitrogen, mmol/L | 5.3 (7.4, 10.8) | 7.5 (6.1, 8.6) | 8.1 (5.6, 12.5) | .247 |
| Creatinine, μmol /L | 81.0 (59.0, 107.0) | 81.0 (62.0, 95.0) | 84.3 (57.7, 116.4) | .320 |
| Lactate dehydrogenase, U/L | 577.0 (440.0, 826.0) | 483.0 (351.0, 602.0) | 767.0 (504.0, 1026.0) | < .001 |
| Troponin I, ng/mL | 0.04 (0.02, 0.20) | 0.03 (0.03, 0.05) | 0.14 (0.02, 0.37) | .014 |
| Type B natriuretic peptide, pg/mL | 217.0 (60.0, 1072.0) | 619.0 (264.0, 2159.0) | 169 (46.5, 649) | .009 |
| Infection and immunity | ||||
| Procalcitonin, ng/mL | 0.4 (0.1, 2.6) | 0.1 (0.0, 0.24) | 1.0 (0.5, 5.9) | < .001 |
| C-reactive protein, mg/dL | 22.8 (10.0, 88.9) | 87.2 (32.6, 104.5) | 11.7 (7.9, 19.8) | < .001 |
| CD3+ T lymphocyte (/μL) | 243 (141, 363) | 193 (98, 295) | 303 (198, 495) | .007 |
| CD4+CD3+ T lymphocyte (/μL) | 150 (75, 240) | 97 (57, 194) | 185 (119, 299) | < .001 |
| CD8+CD3+ T lymphocyte (/μL) | 82 (46, 136) | 70 (36, 116) | 89 (58, 150) | .073 |
| CD4+/CD8+ T lymphocyte | 1.8 (1.3, 2.6) | 1.6 (1.0, 2.3) | 2.2 (1.5, 2.8) | .125 |
| Arterial blood gas analysis | ||||
| pH | 7.42 (7.36, 7.45) | 7.48 (7.45, 7.52) | 7.42 (7.36, 7.45) | .099 |
| Pao2, mm Hg | 74.6 (64.0, 89.0) | 58.0 (49.0, 67.0) | 74.6 (64.0, 89.0) | .018 |
| Paco2, mm Hg | 38.0 (32.0, 44.0) | 35.0 (31.5, 39.5) | 38.0 (32.0, 43.9) | .253 |
| Pao2/Fio2, mm Hg | 138.0 (92.0, 207.3) | 198.5 (147.6, 255.2) | 107.0 (76.0, 148.0) | < .001 |
| Lung CT scan | ||||
| Ground-glass opacity | 103 (69.6) | 69 (94.5) | 34 (45.3) | < .001 |
| Consolidation | 55 (37.2) | 21 (28.8) | 34 (45.3) | .042 |
| Mixed manifestationa | 37 (25.0) | 21 (28.8) | 16 (21.3) | .345 |
Data are presented as medians (interquartile ranges) or No. (%). ALT = alanine aminotransferase; AST = aspartate transaminase. See Table 1 legend for expansion of other abbreviations.
a
Ground-glass opacity with consolidation.